Research programme: stapled peptide therapeutics - Aileron Therapeutics

Drug Profile

Research programme: stapled peptide therapeutics - Aileron Therapeutics

Alternative Names: ATSP-9172; BID-BH3; BIDsp; BIM-BH3; BIM-SAHB; BIMsp

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Aileron Therapeutics
  • Class Peptides
  • Mechanism of Action Apoptosis stimulants; Hypoxia-inducible factor-1 alpha inhibitors; Proto-oncogene protein c-bcl-2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Multiple myeloma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 10 Apr 2013 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Cancer presented at the 104th Annual Meeting of the American Association for Cancer Research (AACR-2013)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top